HIPAA Alert: Potential Data Breach Learn More

Multiple Myeloma

Multiple Myeloma

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

43 Clinical Trials
Multiple Myeloma Phase II Enrolling
nct/study# NCT06171685 / MMRC-099

MMRC Horizon One: A Phase II Randomized adaptive platform Trial evaluating novel therapies in relapsed or refractory multiple myeloma

Learn More
Multiple Myeloma N/A Enrolling
nct/study# N/A / WALDENSTROM

Real world experience with KCD-R management in patients with newly diagnosed Waldenstrom Macroglobulinemia

Learn More
Multiple Myeloma N/A Enrolling
nct/study# NCT02884102 / MMRF-002

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Learn More
Multiple Myeloma N/A Enrolling
nct/study# N/A / MOFFIT-CHIMERIC

Characteristics and Outcomes of Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T Cell Therapy”

Learn More
Multiple Myeloma N/A Enrolling
nct/study# N/A / MOLECULAR-ANALYSIS-IST

Prognostic significance of cytogenetic abnormalities and molecular classification on mortality and morbidity at Hackensack Meridian Health in patients treated for multiple myeloma

Learn More
Multiple Myeloma N/A Enrolling
nct/study# N/A / ONJ-MYELOMA

Comparative Analysis of Osteonecrosis of the Jaw Incidence in Multiple Myeloma Patients Treated with Denosumab vs. Bisphosphonates: A Retrospective Cohort Study

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.